Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Research Shows Marijuana Extract Improves Behavior of Autistic Kids, Teens

New findings shared at the 2025 European Congress of Psychiatry suggest that cannabidiol (CBD), a compound found in marijuana, may offer behavioral benefits for teens and children with autism spectrum disorder (ASD).

ASD affects roughly one in a hundred children globally. It often involves challenges with communication, emotional expression, social interactions, and a tendency toward repetitive behaviors. In the U.S., diagnoses have surged by roughly 175% from 2011 to 2022, with the latest data from the CDC estimating that 1 in 36 American children are on the spectrum.

Many of these children face behavioral and emotional challenges that go beyond those typically seen in neurotypical youth, often placing a heavy burden on families and caregivers.

Dr. Lara Branco, the lead author of the study, noted that although more adolescents and children are being diagnosed with ASD, treatment options remain limited and are often ineffective.

CBD is a major component of cannabis but does not cause a high like THC. Scientists suggest it interacts with receptors in the body and brain to potentially deliver therapeutic effects without intoxication.

The recent study explored data from three placebo-controlled clinical trials focused on adolescents and children with ASD. It involved a total of 276 youngsters aged 5 to 21 (average age of 10.5 years). About 78 percent of the participants were male. CBD was administered at an initial dose of 1 mg per kilogram of body weight per day, gradually increased to as much as 10 mg/kg.

The research showed that CBD extract led to reduced problem behaviors, lowered anxiety, better sleep, and improvements in social interaction. Notably, these benefits came without an increased risk of side effects. The effects were similar between those taking CBD and those given a placebo, suggesting it is generally safe for use in this group.

European Psychiatric Association President Professor Geert Dom welcomed the results, noting the frustration many families and doctors feel due to the lack of effective therapies for ASD. He expressed hope that findings like these could spark more research and eventually lead to better treatment strategies for the autism community.

Despite the promising results, the researchers pointed out that their analysis had some limitations, including a limited number of trial studies and relatively few participants. They noted that larger, high-quality trial studies are still needed to fully understand the long-term safety and effectiveness of CBD in treating autism symptoms.

Such studies are helping to provide further proof of the therapeutic potential of medical marijuana products from enterprises like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) and other industry actors as research documents how various cannabis compounds can help in addressing different symptoms.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Suggests Patients Have No Problem with Doctors Using Marijuana Off-Duty

A recent survey published in the Hand Surgery Global Online Journal explored how patients feel about their doctors using substances like marijuana, alcohol, and nicotine when off duty. The findings showed that more people were okay with their physician using cannabis recreationally than not, and even more were comfortable if it was for medical reasons.

Despite this, the findings may help guide future research and policy, especially as laws and attitudes continue to shift in different regions. These changing attitudes to cannabis use are in part due to legalization policies that have allowed licensed firms like Aurora Cannabis Corp. (NASDAQ: ACB) (TSX: ACB) and others across the…

420 with CNW — Study Suggests Patients Have No Problem with Doctors Using Marijuana Off-Duty

The survey involved 388 patients at four Pennsylvania orthopedic clinics, where only medical marijuana is legal. Most participants were white, around 55 years old on average, and nearly two-thirds said they had never used marijuana. Eleven percent were frequent users.

Participants responded to whether they were comfortable with their doctor using certain substances outside work hours. Alcohol had the highest acceptance rate, with 64% expressing comfort and only 13% expressing discomfort. Nicotine use followed, with 57% okay with it and 16% not.

When it came to cannabis, patients were more accepting of medical use (56%) than recreational (45%). However, 25% were against recreational use by doctors, compared to 16% for medical use, 16% for nicotine, and 13% for alcohol. Around 19% strongly opposed recreational cannabis use, the highest among all substances.

There was also a noticeable uncertainty about cannabis. About 14% weren’t sure how they felt about prescribed cannabis, while over 16.2% were uncertain about recreational use.

Interestingly, factors like the patients’ education level or personal marijuana use didn’t seem to impact their opinions on whether doctors should use cannabis when not working.

The survey also included questions about CBD and cannabis as part of treatment plans. Just over half (53%) were open to their doctor talking about marijuana as a treatment option, while 40% said they’d be willing to consider using it for medical reasons. For CBD, 55% were open to discussing its use. Still, about 20% of people were unsure about both substances being part of their care.

Researchers noted the wide range of opinions, saying the results reflect ongoing debates around cannabis and its role in healthcare. They pointed out that even with CBD, which doesn’t have psychoactive effects, many patients remained undecided.

The study acknowledged its limitations, such as its focus on a rural, mostly homogeneous group in one state. It also recognized that Pennsylvania’s current cannabis laws could influence how comfortable people are talking about cannabis use.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Dutch Marijuana Growers Applaud Decision to Expand Regulated Sales Experiment

The Dutch government has expanded a state-backed cannabis program to allow legal sales, even though growing it remains against the law in most cases. As of now, cannabis stores in ten cities can offer weed sourced from ten officially licensed growers.

For decades, selling small amounts of cannabis in Dutch coffee shops has been tolerated, but the actual cultivation was still illegal. This setup created a legal loophole where you could sell cannabis but not legally produce it. Rick Bakker, a commercial director of one of the approved growers, Hollandse Hoogtes, called it an overdue fix to a confusing situation.

Roughly 80 coffeeshops are now involved in the trial, which is designed to bring more consistency and safety to the cannabis supply chain. One of the main aims is to address issues tied to illegal cultivation, such as crime and poor quality control.

Hollandse Hoogtes, located close to the German border in Bemmel, produces about 440 pounds of cannabis each week. The facility resembles a standard greenhouse operation but stands out for its strict quality standards. Head grower Benjamin Selma, who previously worked in California’s marijuana industry, says every batch is tested for harmful microbes, heavy metals, cannabinoids, and terpenes. No pesticides are used, and the growing environment is closely monitored.

The facility also uses solar power and eco-friendly packaging as part of its sustainability efforts.

Although the Netherlands was one of the first countries to adopt a tolerant stance on cannabis back in the 1970s, the nation has become stricter in recent years. In places like Amsterdam, coffeeshops have been closing, and public smoking has been restricted in certain areas.

Supporters of the trial believe it’s a key step toward a safer, more transparent marijuana industry. Mayor Paul Depla of Breda highlighted the importance of cooperation between authorities, growers, and shop owners in making the system work.

The plan was first proposed in 2017 after a compromise between conservative and progressive political parties. The government has set a four-year period for the trial during which researchers will monitor its impact on public safety, health, and organized crime. Results from the trial will guide future decisions on national cannabis policy.

For growers like Selma, the shift to legal work is a relief. After years of operating under risky conditions, he said it feels almost unreal to finally produce cannabis without fear of legal consequences.

The participating cities include Zaanstad, Almere, Breda, Arnhem, Groningen, Tilburg, Heerlen, Hellevoetsluis, Nijmegen, and Maastricht.

As the system proves its efficacy, it could trigger opportunities for international players like Trulieve Cannabis Corp. (CNX: TRUL) (OTCQX: TCNNF) interested in expanding their global footprint.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Medical Marijuana Could Reduce Cravings, Boost Addiction Recovery

A recent pilot study by researchers from Thompson Rivers University (TRU) and the University of British Columbia (UBC) Okanagan explored how medically supervised marijuana use might support individuals undergoing treatment for substance use disorders in a residential recovery setting.

The research focused on the experiences of both residents and staff when cannabis was included as part of a recovery plan.

Participants shared that marijuana helped ease symptoms like depression, anxiety, pain, and sleep problems—issues that often make recovery harder. Some also reported fewer cravings for opioids and other addictive substances.

According to Dr. Zach Walsh, a psychology professor involved in the study, these effects suggest that cannabis could help people stick with their recovery programs by making both mental and physical challenges more manageable.

While the findings are encouraging, the researchers noted that stigma remains a big hurdle. Many staff members were skeptical about cannabis as a valid medical tool. Dr. Florriann Fehr, a nursing professor and co-lead on the study, emphasized the importance of educating staff to break down these barriers. “Misinformation and outdated views can prevent cannabis from being used effectively, even when it shows potential,” she added.

The research was carried out at Maverick Supportive Recovery, a live-in recovery facility situated in British Columbia offering structured care for those dealing with substance use. The program creates a stable environment designed to help people recover in a safe and supportive setting.

Although the initial results are positive, the team behind the study says broader research is needed. The authors noted that there is no one-size-fits-all solution, as recovery looks different for everyone, and what works for one person may not work for another. But if cannabis can help someone stay in treatment and manage their symptoms, it’s worth exploring further.

Ultimately, they noted that cannabis is not a replacement for traditional treatments but an additional option that could help certain individuals, especially when used under medical supervision.

To help reduce stigma and share knowledge, events like public forums and professional gatherings are being organized. Dr. Fehr is scheduled to present the study’s findings in June at a global nursing conference in Helsinki. In addition, Thompson Rivers University will host a Medical Cannabis and Recovery forum this April, welcoming the public, healthcare workers, and researchers interested in learning more about this topic.

The study was funded by the British Columbia Ministry of Health and the Interior Universities Research Coalition.

The findings of this small study could suggest to marijuana industry firms like Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) that there is still plenty of room to bring to market innovative cannabis products tailored to the needs of different groups of patients concerned about particular symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds CBD, CBG-Infused Ointment Effective Against Eczema

A recent study has found that a skin ointment containing cannabigerol (CBG) and cannabidiol (CBD) may help ease the symptoms of atopic dermatitis, commonly known as eczema. The research, published in the Clinical, Cosmetic and Investigational Dermatology journal, followed nine adults diagnosed with eczema over three months. The researchers tracked skin health indicators, including moisture levels, oil production, skin pH, and water loss.

Participants used a topical treatment containing 5% CBG, 30% CBD, cholesterol, and hemp seed oil. According to the researchers, applying the ointment daily to affected areas—specifically the forearms—and covering it with a wet wrap before sleep helped improve various skin health markers. These included hydration, oil levels, water loss, and redness.

Some patients even experienced remission of their symptoms. The treatment served as an alternative to more conventional therapies during both flare-ups and periods of remission.

The authors noted better results among participants who consistently followed the application routine. Those who skipped applications or were put off by the greasy feel of the product didn’t experience the same level of improvement.

While the results are promising, the researchers acknowledged that the timing of the study, from May to July of 2022, might have influenced outcomes, since eczema symptoms tend to lessen in warmer months.

This study adds to the growing interest in CBD’s role in skincare. A study from Thailand found that CBD may be useful in cosmetic products thanks to its antioxidant and wound-healing properties. Researchers there suggested that CBD could be added to items like sunscreen, hair products, or healing ointments.

Another study published by a team in the U.S. showed that using CBD-infused lotion might reduce skin damage caused by UV rays. Participants who applied the CBD product experienced less UV-related damage compared to a placebo group.

The potential benefits of cannabinoids may also extend to veterinary care. A 2024 study explored how full-spectrum cannabis oil helped a dog with discoid lupus erythematosus, an autoimmune condition that typically causes hair loss and skin lesions. Traditional steroid treatments had caused liver issues, but switching to cannabis oil—with a CBD to THC ratio of 1:2—led to notable improvement in the dog’s skin and liver health. The dog’s behavior also improved shortly after stopping steroid medication.

Overall, these findings suggest a growing interest in the role of cannabinoids as a potential option for managing various skin conditions in both humans and animals. The findings also show that the full range of therapeutic benefits that can be obtained from the available marijuana products on the market by players like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) has yet to be documented by researchers.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — White House List Shows Cannabis Rescheduling Isn’t a Priority for Now

Cannabis reform is not among President Donald Trump’s top drug policy goals for his first year back in office, according to a statement from the Office of National Drug Control Policy (ONDCP). Instead, the administration plans to prioritize tackling drug trafficking and addressing the opioid epidemic, with a particular focus on substances like fentanyl.

Although cannabis rescheduling efforts began under President Biden, progress has stalled due to complications with DEA hearings. Supporters of cannabis reform had hoped Trump would take action, especially since he expressed support for the idea during his campaign. However, he has remained quiet on the matter since taking office again, and the new drug policy roadmap makes no mention of marijuana.

Despite cannabis being left out, the administration also hasn’t indicated it will increase enforcement against cannabis like it plans to with drugs such as meth, heroin, cocaine, xylazine, and fentanyl. That neutrality may come as a relief to reform advocates. Some parts of the plan could even be seen as positive, such as efforts to broaden access to naloxone—the medication that reverses opioid overdoses—and pushing states to make drug test strips more available to the public.

The ONDCP says the president’s policy focus may expand over time as drug trends evolve. For now, the administration is emphasizing enforcement and prevention measures to protect communities, schools, and the border from the dangers of illegal substances.

Cannabis supporters argue that legal marijuana could help reduce opioid addiction and deaths, pointing to studies that show lower rates of opioid use in states where medical cannabis is available. With Trump having previously voiced support for medical marijuana, the complete omission of cannabis from the current plan is seen by some as a missed chance to incorporate a potential tool in the fight against opioids.

Whether this stance could shift remains uncertain. Trump’s nominee to lead the ONDCP, Sara Carter, has described medical cannabis as a “fantastic” option for people with serious health conditions and said she doesn’t oppose legalization, even if she’s not fully on board with it personally.

The policy update follows the White House’s announcement that there are no active plans for cannabis reform. While rescheduling is stalled, others had hoped the administration would at least push forward with cannabis banking legislation. According to CNN, Trump tried to include such a measure in a spending bill before returning to office, but it didn’t make it through.

Marijuana firms like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) will be watching to see whether the Trump administration finally gets round to completing the rescheduling work that was started under the previous administration. This policy change could usher in a new era for the industry.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — FBI Stance on Background Check Request Upends Delaware’s Marijuana Market Launch

Plans to launch recreational marijuana sales in Delaware this spring have hit a major roadblock following an announcement by the state’s Office of the Marijuana Commissioner (OMC) that the FBI had denied their updated service code request. The code is required to perform fingerprint-based background checks, which is a prerequisite for the impending recreational market.

The fate of Delaware’s recreational marijuana market now rests on lawmakers’ ability to revise legislation and meet federal requirements. The current roadblock is likely to set back not just marijuana firms but also ancillary companies operating in the format of Innovative Industrial Properties Inc. (NYSE: IIPR) that were gearing up…

420 with CNW — FBI Stance on Background Check Request Upends Delaware’s Marijuana Market Launch

The OMC had been collaborating with the state Justice Department and the State Bureau of Identification (SBI) to obtain the service code. However, a dispute between state and federal regulations means lawmakers will have to draft new legislation that aligns with the FBI’s standards.

The state General Assembly remains in session until June 30, so the timeline for resolving this issue remains uncertain.

This delay comes approximately two years after former Governor John Carney permitted the approval of two recreational marijuana measures without signing them. Last year, lawmakers passed additional legislation to clarify and correct certain provisions in the prior Act, including amendments to state codes.

One key requirement mandates that recreational cannabis license applicants submit fingerprints for the SBI to retrieve their FBI criminal history records. However, the agency has now ruled that Delaware’s legislation was not properly structured, further complicating the approval process for 125 cannabis license recipients.

This uncertainty poses financial risks for the awarded licenses, particularly if they are paying rent for facilities without being able to generate revenue. The OMC held lotteries in October last year, granting 110 licenses to testing labs, cultivators, social equity candidates, and manufacturers. In December, another lottery round awarded fifteen licenses to standard dispensaries.

Before stepping down in January 2025, Rob Coupe, the state’s first cannabis commissioner, had aimed for sales to begin in March. Now with the FBI roadblock in place, an alternative path could involve leveraging the state’s existing medical marijuana licensees.

Coupe had worked with legislators to draft a measure permitting the medical marijuana businesses to transition into the recreational market. The legislation, signed into law by Carney in July last year, allows medical dispensaries to convert their licenses by paying conversion fees—$100,000 for testing, retail, and manufacturing permits, and $200,000 for cultivation licenses.

The fee system could generate over $4 million, which legislators have allocated to support social equity applicants.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — US Supreme Court Gives Truck Driver the Nod to Pursue Racketeering Charges Against Marijuana Company

The United States Supreme Court has ruled against Medical Marijuana Inc. in a case involving a truck driver who lost his job after he failed a drug test. The driver, Douglas Horn, claimed he was misled into using a cannabidiol (CBD) product that was falsely advertised as THC-free. THC is the psychoactive compound in cannabis responsible for its intoxicating effects.

In a narrow 5 to 4 decision, Justice Amy Coney Barrett wrote the majority opinion, upholding a lower court ruling that permitted Horn to sue the company, based in San Diego, under the Racketeer Influenced and Corrupt Organizations Act (RICO).

RICO, a 1970 law originally aimed at curbing organized crime, allows individuals to seek triple damages if they suffer business or property losses due to certain illegal activities.

The central issue in the case was whether Horn’s job loss constituted the type of injury covered by RICO. The court determined that his firing fit the legal definition of harm, rejecting Medical Marijuana’s argument to the contrary. Barrett stated in the court’s ruling that the company had no viable alternative interpretation of the statute.

Horn, who had sustained injuries in a trucking accident, purchased Medical Marijuana’s CBD tincture—Dixie X—in 2012. The product was marketed as a natural pain remedy that contained no THC. However, a random drug test by his employer later detected THC in his blood system, leading to his termination after more than ten years on the job. Horn maintains he has never used cannabis.

In 2015, Horn filed a lawsuit in a New York federal court seeking financial compensation. They accused Medical Marijuana and its affiliates of violating RICO by engaging in a pattern of fraudulent activities, including wire and mail fraud, as well as violations of the Controlled Substances Act (CSA). A laboratory test later confirmed that the tincture did, in fact, contain THC.

Initially, a federal trial judge dismissed Horn’s RICO Act claim. However, the second U.S. Circuit Court of Appeals in New York overturned that decision, allowing the lawsuit to proceed. Medical Marijuana subsequently appealed to the Supreme Court, which heard arguments on the case on October 15, 2024, before issuing its final ruling.

The ruling sets a precedent, potentially allowing others in similar situations to seek damages under RICO if they can prove financial harm due to mislabeled or misleadingly marketed marijuana products.

The decision of the Supreme Court is likely to be seen by many marijuana companies, including SNDL Inc. (NASDAQ: SNDL), as a reminder to all businesses to be particular about the information they include on product labels since any mistakes or misinformation can have serious ramifications for their clients and the companies themselves.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com